Ovid Therapeutics Inc.
Ovid Therapeutics Inc. (OVID) Revenue
Annual & quarterly revenue history · segment & region breakdown
OVID · revenue · updated Jun 9, 2026
Core revenue metrics
Trailing 12 monthsOvid Therapeutics Inc. trailing twelve-month (TTM) revenue is $0.01B, an increase of 1181.27% year-over-year from $0.01B in FY2025.
Revenue trend
2025 – 2014 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2025-12-31 | $0.01B | +$0.01B | +1181.27% |
| 2024-12-31 | $0.00B | +$0.00B | +44.39% |
| 2023-12-31 | $0.00B | -$0.00B | -73.91% |
| 2022-12-31 | $0.00B | -$0.21B | -99.28% |
| 2021-12-31 | $0.21B | +$0.20B | +1551.57% |
| 2020-12-31 | $0.01B | +$0.01B | — |
| 2019-12-31 | $0.00B | +$0.00B | — |
| 2018-12-31 | $0.00B | +$0.00B | — |
| 2017-12-31 | $0.00B | +$0.00B | — |
| 2016-12-31 | $0.00B | +$0.00B | — |
Revenue breakdown
Segment & GeographyAbout Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Ovid Therapeutics Inc. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Ovid Therapeutics Inc. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from Ovid Therapeutics Inc.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
OVID revenue · 4 questionsOVID's trailing twelve-month (TTM) revenue is $0.01B. That is an increase of 1181.27% year-over-year from $0.01B in FY2025.
▸ Source: FMP · Ovid Therapeutics Inc. SEC filings · GAAP · Ovid Therapeutics Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026